ATE414541T1 - Vitronectin rezeptor antagonist pharmaka - Google Patents

Vitronectin rezeptor antagonist pharmaka

Info

Publication number
ATE414541T1
ATE414541T1 AT01952180T AT01952180T ATE414541T1 AT E414541 T1 ATE414541 T1 AT E414541T1 AT 01952180 T AT01952180 T AT 01952180T AT 01952180 T AT01952180 T AT 01952180T AT E414541 T1 ATE414541 T1 AT E414541T1
Authority
AT
Austria
Prior art keywords
receptor antagonist
treatment
vitronectin receptor
pharmaceuticals
present
Prior art date
Application number
AT01952180T
Other languages
English (en)
Inventor
Thomas Harris
John Barrett
Alan Carpenter
Milind Rajopadhye
Original Assignee
Lantheus Medical Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantheus Medical Imaging Inc filed Critical Lantheus Medical Imaging Inc
Application granted granted Critical
Publication of ATE414541T1 publication Critical patent/ATE414541T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
AT01952180T 2000-06-21 2001-06-21 Vitronectin rezeptor antagonist pharmaka ATE414541T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21321000P 2000-06-21 2000-06-21

Publications (1)

Publication Number Publication Date
ATE414541T1 true ATE414541T1 (de) 2008-12-15

Family

ID=22794168

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01952180T ATE414541T1 (de) 2000-06-21 2001-06-21 Vitronectin rezeptor antagonist pharmaka

Country Status (12)

Country Link
EP (1) EP1307226B1 (de)
JP (1) JP2004521066A (de)
CN (1) CN1582166A (de)
AT (1) ATE414541T1 (de)
AU (2) AU7296501A (de)
BR (1) BR0111880A (de)
CA (1) CA2412854C (de)
DE (1) DE60136632D1 (de)
IL (1) IL152941A0 (de)
MX (1) MXPA02012750A (de)
NZ (1) NZ522925A (de)
WO (1) WO2001097848A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6693093B2 (en) 2000-05-08 2004-02-17 The University Of British Columbia (Ubc) Drug delivery systems for photodynamic therapy
EP1311292A2 (de) * 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Vitronectin rezeptor antagonist pharmaka
NZ534500A (en) 2002-01-24 2007-07-27 Barnes Jewish Hospital Nanoparticle-based emulsions specifically targeted to integrins
EP1475105A1 (de) * 2003-05-09 2004-11-10 Schering AG Knochengewebegerichtetes Radiopharmaceuticum und Tubulin-interagierende Verbindung kombinatorischer Radiotherapie
WO2004100996A1 (en) * 2003-05-12 2004-11-25 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals
EP3101012A1 (de) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Neue gadoliniumchelat-verbindung zur verwendung in der magnetresonanzbildgebung
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
US11090395B2 (en) * 2018-09-14 2021-08-17 SeeCure Taiwan Co., Ltd. Composition for cross talk between estrogen receptors and cannabinoid receptors
EP3883613A1 (de) 2018-11-23 2021-09-29 Bayer Aktiengesellschaft Formulierung für kontrastmittel und verfahren zur herstellung davon

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270475T3 (es) * 1996-11-27 2007-04-01 Bristol-Myers Squibb Pharma Company Nuevos antagonistas de receptores de integrina.
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
CA2727746A1 (en) * 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
WO2001098294A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
EP1311292A2 (de) * 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Vitronectin rezeptor antagonist pharmaka
JP2005538030A (ja) * 2000-06-21 2005-12-15 デュポン ファーマシューティカルズ カンパニー 組み合わせ療法での使用のための血管新生障害の画像診断用医薬
AU2002218751A1 (en) * 2000-07-06 2002-01-21 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions

Also Published As

Publication number Publication date
WO2001097848A2 (en) 2001-12-27
WO2001097848A3 (en) 2003-03-13
IL152941A0 (en) 2003-06-24
EP1307226A2 (de) 2003-05-07
CN1582166A (zh) 2005-02-16
EP1307226B1 (de) 2008-11-19
CA2412854A1 (en) 2001-12-27
CA2412854C (en) 2010-08-17
AU7296501A (en) 2002-01-02
NZ522925A (en) 2006-08-31
MXPA02012750A (es) 2004-07-30
AU2001272965B2 (en) 2005-11-17
BR0111880A (pt) 2006-04-25
JP2004521066A (ja) 2004-07-15
DE60136632D1 (de) 2009-01-02
AU2001272965C1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
WO2001098294A3 (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
WO2001097861A3 (en) Vitronectin receptor antagonist pharmaceuticals
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
WO2001097860A3 (en) Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
WO2000035492A3 (en) Vitronectin receptor antagonist pharmaceuticals
BG107171A (bg) Производни на пурин
DK1648925T3 (da) Bicyklisk peptid-billeddannende midler
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
BR0015420A (pt) Composto, composição farmacêutica, métodos de tratamento de uma doença ou de um distúrbio associados com agonismo patogênio, para a localização de receptores gabaa, em uma amostra de tecido, de inibição da ligação de um composto de benzodiazepina em um receptor gabaa, e de alteração da atividade de transdução de sinal de receptores gabaa, agonismo inverso ou antagonismo do receptor gabaa, uso de um composto, e , composição faramcêutica embalada
BR0116379A (pt) Antagonistas de receptor y5 de neuropeptìdeo y de uréia de heteroarila
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
CY1110243T1 (el) Ανταγωνιστες npyy5
WO1999058162A3 (en) Pharmaceuticals for the imaging of angiogenic disorders
EP1641423A4 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
BRPI0011856B8 (pt) agonistas de receptor a2a de n-pirazol
DE60136632D1 (de) Vitronectin rezeptor antagonist pharmaka
EP1372741A4 (de) Morpholinobildgebung und therapie
NO20031323L (no) Peptid-baserte forbindelser
TR199701647A2 (xx) �kame edilmi� purin t�revleri,bunlar�n imalat usul�
DE60121461D1 (de) Kondensierte pyridoindolderivate
DE60001586D1 (de) Diphenyl-piperidin derivate
TR200103680T2 (tr) IL-8 reseptör antagonistleri.
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
DK1140203T3 (da) Farmaceutiske præparater som vitronectinreceptorantagonist
TR199901761T2 (xx) IL-8 resept�r antagonistleri.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties